BNT162b2疫苗在意大利5-11岁儿童中预防SARS-CoV-2感染和重症COVID-19的效果:2022年1-4月回顾性分析
该回顾性人群分析链接意大利国家COVID-19监测系统与疫苗接种登记,纳入2022年1月17日至4月13日所有无既往感染诊断的5-11岁儿童。全程接种(两剂)组疫苗对SARS-CoV-2感染的效果为29.4%(95%CI 28.5-30.2),对重症COVID-19(感染导致住院或死亡)为41.1%(22.2-55.4);部分接种(一剂)组分别为27.4%(26.4-28.4)和38.1%(20.9-51.5)。对感染的效果在全程接种后0-14天达峰值38.7%(37.7-39.7),至43-84天降至21.2%(19.7-22.7)。作者认为,意大利5-11岁儿童接种COVID-19疫苗预防SARS-CoV-2感染和重症COVID-19的效果低于12岁及以上人群,且完成当前基础免疫程序后对感染的效果似乎下降。
要点
- 全程接种(两剂)BNT162b2对5-11岁儿童SARS-CoV-2感染的效果为29.4%(95%CI 28.5-30.2),对重症COVID-19为41.1%(22.2-55.4)。
- 部分接种(一剂)对SARS-CoV-2感染的效果为27.4%(26.4-28.4),对重症COVID-19为38.1%(20.9-51.5)。
- 对感染的效果在全程接种后0-14天为38.7%(37.7-39.7),43-84天降至21.2%(19.7-22.7)。
- 研究期间共报告766 756例SARS-CoV-2感染和644例重症COVID-19(627例住院、15例ICU入住、2例死亡)。
- 截至2022年4月13日,纳入的2 965 918名儿童中全程接种1 063 035人(35.8%)、部分接种134 386人(4.5%)、未接种1 768 497人(59.6%)。
适用人群与场景
- 意大利5-11岁儿童,无既往SARS-CoV-2感染诊断,随访期为2022年1月17日至4月13日。
- 排除疫苗接种数据不一致、研究开始前已诊断SARS-CoV-2感染或无居住市镇信息的儿童。
诊断标准与关键阈值
- 重症COVID-19定义为导致住院或死亡的SARS-CoV-2感染。
- 部分接种定义为仅接种一剂BNT162b2,全程接种定义为接种两剂BNT162b2。
研究设计与关键结果
- 研究类型为回顾性人群分析,链接意大利国家COVID-19监测系统与全国疫苗接种登记,纳入2 965 918名5-11岁儿童。
- 截至2022年4月13日,全程接种1 063 035人(35.8%),部分接种134 386人(4.5%),未接种1 768 497人(59.6%)。
- 研究期间报告766 756例SARS-CoV-2感染和644例重症COVID-19(627例住院、15例ICU入住、2例死亡)。
- 以未接种儿童为参照,全程接种组对SARS-CoV-2感染的效果为29.4%(95%CI 28.5-30.2),对重症COVID-19为41.1%(22.2-55.4)。
- 部分接种组对SARS-CoV-2感染的效果为27.4%(26.4-28.4),对重症COVID-19为38.1%(20.9-51.5)。
- 对感染的效果在全程接种后0-14天为38.7%(37.7-39.7),43-84天降至21.2%(19.7-22.7)。
证据类型、等级与局限
- 证据类型:回顾性人群分析。
- 作者结论:意大利5-11岁儿童接种COVID-19疫苗预防SARS-CoV-2感染和重症COVID-19的效果低于12岁及以上人群,完成当前基础免疫程序后对感染的效果似乎下降。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该结果可用于 informing 公共卫生机构制定疫苗接种政策和策略(原文未据此给出具体临床推荐)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: By April 13, 2022, more than 4 months after the approval of BNT162b2 (Pfizer-BioNTech) for children, less than 40% of 5-11-year-olds in Italy had been vaccinated against COVID-19. Estimating how effective vaccination is in 5-11-year-olds in the current epidemiological context dominated by the omicron variant (B.1.1.529) is important to inform public health bodies in defining vaccination policies and strategies.
METHODS: In this retrospective population analysis, we assessed vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19, defined as an infection leading to hospitalisation or death, by linking the national COVID-19 surveillance system and the national vaccination registry. All Italian children aged 5-11 years without a previous diagnosis of infection were eligible for inclusion and were followed up from Jan 17 to April 13, 2022. All children with inconsistent vaccination data, diagnosed with SARS-CoV-2 infection before the start date of the study or without information on the municipality of residence were excluded from the analysis. With unvaccinated children as the reference group, we estimated vaccine effectiveness in those who were partly vaccinated (one dose) and those who were fully vaccinated (two doses).
FINDINGS: By April 13, 2022, 1 063 035 (35·8%) of the 2 965 918 children aged 5-11 years included in the study had received two doses of the vaccine, 134 386 (4·5%) children had received one dose only, and 1 768 497 (59·6%) were unvaccinated. During the study period, 766 756 cases of SARS-CoV-2 infection and 644 cases of severe COVID-19 (627 hospitalisations, 15 admissions to intensive care units, and two deaths) were notified. Overall, vaccine effectiveness in the fully vaccinated group was 29·4% (95% CI 28·5-30·2) against SARS-CoV-2 infection and 41·1% (22·2-55·4) against severe COVID-19, whereas vaccine effectiveness in the partly vaccinated group was 27·4% (26·4-28·4) against SARS-CoV-2 infection and 38·1% (20·9-51·5) against severe COVID-19. Vaccine effectiveness against infection peaked at 38·7% (37·7-39·7) at 0-14 days after full vaccination and decreased to 21·2% (19·7-22·7) at 43-84 days after full vaccination.
INTERPRETATION: Vaccination against COVID-19 in children aged 5-11 years in Italy showed a lower effectiveness in preventing SARS-CoV-2 infection and severe COVID-19 than in individuals aged 12 years and older. Effectiveness against infection appears to decrease after completion of the current primary vaccination cycle.
TRANSLATION: For the Italian translation of the summary see Supplementary Materials section.
参考来源
- Sacco C, Del Manso M, Mateo-Urdiales A, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022. Lancet. 2022. PMID: 35780801. doi:10.1016/S0140-6736(22)01185-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。